Overview
Synthaverse is a Polish biotechnology company that has been operating since 1944, specializing in the development of immunotherapy solutions for various medical fields, including oncology, urology, gynecology, and tuberculosis treatment. The company offers products such as ONKO BCG, DAVOSTER, and DISTREPTAZA, aimed at supporting patients and the medical community.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 2.82
- High
- PLN 2.83
- Low
- PLN 2.76
- Volume
- 28.78K
- Avg. vol.
- 33.53K
- Market cap
- PLN 214.37M
- P/E ratio
- —
- EPS
- -PLN 0.28
- Shares outstanding
- 76.02M
- 52-week
- PLN 2.76 – 2.93
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLBMDLB00018
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 3.47m | USD -182.87k | USD -745.54k |
| Q1 2026 | USD 3.68m | USD -179.90k | USD -974.07k |
| Q4 2025 | USD 4.40m | USD -1.96m | USD -1.73m |
| Q3 2025 | USD 1.20m | USD -1.86m | USD -1.94m |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2003-09-30. Active
36 1050 1953 1000 0090 8681 3053- 27 1050 1953 1000 0090 8107 4792
- 30 1050 1953 1000 0090 8108 0849
Debt
1 closed proceeding recorded in KRZ history. Closed proceedings in history
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Oct 25, 2024 | Declaration of arrangement performance in restructuring | Closed |
MSiG notices
36 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Oct 18, 2024 | Bankruptcy notice | |
| Jul 24, 2024 | Bankruptcy notice | |
| Apr 18, 2024 | Bankruptcy notice | |
| Jan 17, 2024 | Bankruptcy notice | |
| Oct 30, 2023 | Bankruptcy notice |
Public aid
43 public aid cases recorded, with a total value of $24,963,309.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 27, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $5,048 | Lubelski Park Naukowo -Technologiczny S.A. | |
| Mar 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,952 | Prezydent Miasta Lublin | |
| Dec 19, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $2,009 | Prezes Banku Gospodarstwa Krajowego |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $18,006,964.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-06-01 | Wdrożenie wyników prac B+R w zakresie innowacyjnej technologii wytwarzania produktu do immunoterapii raka pęcherza moczowego w oparciu o podszczep Moreau atenuowanych prątków gruźlicy BCG | $9,681,039 | Program Operacyjny Inteligentny Rozwój | |
| 2021-01-01 | Promocja Onko BCG - leku stosowanego w leczeniu powierzchownych, nabłonkowych, nieinwazyjnych guzów pęcherza moczowego na rynkach zagranicznych | $76,566 | Program Operacyjny Inteligentny Rozwój | |
| 2020-12-01 | Centrum innowacji biotechnologicznych BCG | $7,481,911 | Program Operacyjny Inteligentny Rozwój |
Tenders
3 tenders recorded as contractor, with a total value of $11,169.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Dec 30, 2022 | Dostawa odczynników chemicznych, diagnostycznych i wzorców dla Wojewódzkiej Stacji Sanitarno-Epidemiologicznej w Bydgoszczy | $1,465 | Wojewódzka Stacja Sanitarno - Epidemiologiczna w Bydgoszczy | |
| Aug 25, 2022 | Sukcesywna dostawa odczynników chemicznych i materiałów mikrobiologicznych dla Wojewódzkiej Stacji Sanitarno- Epidemiologicznej w Rzeszowie- II procedura | $8,410 | Wojewódzka Stacja Sanitarno - Epidemiologiczna w Rzeszowie | |
| Mar 29, 2022 | Dostawa odczynników laboratoryjnych, chemicznych wraz z dzierżawą analizatorów oraz aparatów - Pakiet nr 12 Dostawa podłoży bakteriologicznych - Podłoże Lowensteina-Jansena, zestawy do lekooporności | $1,294 | Samodzielny Zespół Publicznych Zakładów Lecznictwa Otwartego Warszawa Praga-Północ |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Integrated permit | Active |
Authorized Representatives
Manner of representation
For making declarations of will concerning the rights and obligations of the company and for signing on behalf of the company, the following are authorized: in the case of a one-person management board, the President independently, or two commercial proxies jointly. In the case of a multi-member management board: the President of the Management Board jointly with a member of the management board, or two members of the management board jointly, or a member of the management board jointly with a commercial proxy, or two commercial proxies jointly. Matters exceeding the ordinary management of the company require a resolution of the management board.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Artur Chodkowski (51)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Dariusz Kucowicz (61) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Jakub Tadeusz Winkler (42) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| PolfarmexS.A. | $73,543,379.32 | polfarmex.pl | |
| BiotonS.A. | $72,911,351.08 | bioton.com | |
| Phytopharm KlękaS.A. | $46,154,888.31 | phytopharm.pl | |
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | |
| VipharmS.A. | $30,660,173.61 | vipharm.pl | |
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | |
| PoltregS.A. | $1,906,011.66 | poltreg.com |
Change history
| Date | Event |
|---|---|
| 2026-07-29 | Share capital change (7,577,057.50 PLN → 7,601,940.30 PLN) |
| 2025-11-19 | Share capital change (7,077,057.50 PLN → 7,577,057.50 PLN) |
| 2024-12-12 | Share capital change (7,052,197.30 PLN → 7,077,057.50 PLN) |
| 2024-02-14 | Share capital change (7,026,041.00 PLN → 7,052,197.30 PLN) |
| 2023-07-10 | Name change ("biomed-Lublin" Wytwórnia Surowic I Szczepionek → "synthaverse") |
FAQ
Last updated: 2026-08-07